What the Source Covers
A recent piece in Psychiatric Times surveys how clinicians are navigating treatment-resistant depression (TRD) in 2026, with particular attention to esketamine (Spravato) as a rapid-acting glutamatergic option. The article examines patient preference data, the structural barriers that continue to limit access to this treatment, and the clinical scenarios — particularly acute suicidal ideation — where the speed of esketamine's mechanism offers a meaningful advantage over conventional antidepressants. Read the original source at Psychiatric Times.
Why Esketamine Matters in the Ketamine Conversation
Esketamine and racemic ketamine are closely related but not identical. Esketamine is the S-enantiomer of ketamine — meaning it's one of the two mirror-image molecular forms that make up standard IV ketamine infusions. Spravato, the FDA-approved intranasal formulation, delivers esketamine directly and carries formal regulatory approval specifically for TRD and major depressive disorder with acute suicidal ideation (MDSI). This distinction matters for anyone researching low-dose ketamine treatment options, because it shapes the clinical context in which each form is used and studied.
The Psychiatric Times overview reinforces something the research has suggested for several years now: the glutamatergic mechanism — essentially, the way ketamine-class compounds rapidly modulate NMDA receptors and downstream AMPA signaling — is what separates these treatments from traditional antidepressants in time-to-response. Where SSRIs and SNRIs may require weeks before meaningful symptom relief, esketamine can produce measurable antidepressant effects within hours to days. For a patient in acute crisis, that difference is clinically significant.
Access Barriers Remain a Persistent Problem
One of the more practically important threads in the Psychiatric Times piece is the ongoing discussion of access. Despite FDA approval, esketamine remains difficult to obtain for many patients. The REMS (Risk Evaluation and Mitigation Strategy) program requires administration in a certified healthcare setting with a two-hour post-dose observation window, which creates logistical friction — particularly for patients in rural areas, those without flexible work schedules, and those with limited insurance coverage.
This is not a new problem, but the article's framing in 2026 suggests it hasn't been resolved. Clinicians are still making individualized decisions about whether to pursue esketamine through certified centers or to consider off-label IV ketamine infusions, which operate outside the REMS framework but also outside formal insurance coverage in most cases. Neither pathway is frictionless.
For patients and families weighing options, this is a real-world constraint that shapes what's actually available, not just what's theoretically effective.
Patient Preferences and Shared Decision-Making
The article also touches on patient preference data, which is an underappreciated variable in the TRD treatment landscape. Some patients are deterred by the dissociative side effects associated with ketamine-class treatments — the transient perceptual shifts, derealization, or dizziness that can accompany a session. Others specifically report that the altered-state experience feels meaningful or tolerable in exchange for rapid symptom relief. Clinician guidance increasingly incorporates these preferences rather than treating ketamine-class treatment as a uniform last resort.
For readers of this site who are in the early stages of evaluating low-dose ketamine, this is a useful reminder: your subjective experience of treatment matters and should be part of the clinical conversation. The dose, delivery method, setting, and frequency are all adjustable variables — the goal is a protocol that is both effective and sustainable for you specifically.
Key Takeaway
Esketamine (Spravato) and off-label IV ketamine operate through similar mechanisms but occupy different regulatory and access landscapes. The evidence for rapid antidepressant effect in TRD is meaningful, but access barriers, insurance limitations, and individual tolerability all shape whether a given patient can realistically pursue either pathway. If you're researching low-dose ketamine for depression, discuss both options with a clinician who is familiar with both the esketamine REMS program and IV ketamine protocols — they are not interchangeable, and the right fit depends on your clinical picture, geography, and practical circumstances.
What This Means for Low-Dose Ketamine Patients and Researchers
The continued clinical attention to esketamine in TRD is good news for the broader ketamine field. Peer-reviewed coverage in publications like Psychiatric Times reflects a maturing evidence base and a treatment modality that is moving — slowly but visibly — toward mainstream psychiatric practice. Each publication that examines dosing rationale, patient selection, and safety monitoring helps establish clearer clinical norms, which benefits patients by setting more consistent expectations and improving clinician training.
For those already in low-dose ketamine treatment, the key implication is continuity: the science supporting rapid glutamatergic interventions for depression is not softening. If anything, the clinical discussion is becoming more nuanced, with greater attention to maintenance protocols, responder profiles, and how to manage patients who experience initial relief but require ongoing support to sustain it. These are the questions that matter most over the long term, and they're increasingly the questions the field is asking.
Evidence quality note: This analysis is based on a clinical overview article rather than a primary research study or meta-analysis. It reflects current practitioner thinking and should be interpreted accordingly — informative for understanding how the field is evolving, but not a substitute for individualized clinical guidance.
Share